Condition
Tingling
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
Early P 1 (1)
P 2 (2)
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06799351Phase 2Recruiting
Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
NCT06706544Phase 2Recruiting
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
NCT03943498Early Phase 1Completed
Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy
NCT02722434Not ApplicableCompleted
MC5-A Scrambler Therapy or TENS Therapy in Treating Patients With Chemotherapy-Induced Peripheral Neuropathy
NCT03206216Not ApplicableTerminated
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Showing all 5 trials